SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ogawa, R. Articles by Kato, G. J. Search for Related Content PubMed PubMed Citation Articles by Ogawa, R. Articles by Kato, G. J. Related Collections Neoplasia Apoptosis Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 May 2002, Vol. 99, No. 9, pp. 3390-3397 NEOPLASIA Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21WAF1/CIP1 proteins in human acute lymphoblastic leukemia cells Ryosuke Ogawa, Michael B. Streiff, Artem Bugayenko, and Gregory J. Kato From the Division of Hematology, Department of Pediatrics, Department of Medicine and the Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Glucocorticoids are integral to successful treatment of childhood acute lymphoblastic leukemia (ALL) and other lymphoid malignancies. A large body of data indicates that in various model systems, elevation of cyclic adenosine monophosphate (cAMP) can potentiate glucocorticoid response, although this has not been well evaluated as a potential leukemia treatment. Although cAMP analogs have been studied, little data exist regarding the potential toxicity to leukemia cells of pharmacologic elevation of cAMP levels in leukemic blasts. Using MTT assays of cell proliferation on CEM ALL cells, we found that aminophylline and other nonspecific phosphodiesterase (PDE) inhibitors suppress cell growth. This effect is replicated by the PDE4-specific PDE inhibitor rolipram, but not by specific inhibitors of the PDE1 or PDE3 classes. We found that PDE inhibitors cause increased dexamethasone sensitivity and a synergistic effect with the adenylyl cyclase activator forskolin. We observed several important cellular characteristics associated with this treatment, including elevation of cAMP, induction of p53 and p21WAF1/CIP1 proteins, G1 and G2/M cell cycle arrest, and increased apoptosis. Sensitivity to forskolin and rolipram is shared by at least 2 pediatric ALL cell lines, CEM and Reh cells. Some cell lines derived from adult-type lymphoid malignancies also show sensitivity to this treatment. These findings suggest that PDE inhibitors have therapeutic potential in human ALL and characterize the molecular mechanisms that may be involved in this response. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L.-H. Zhang, L. Wu, H. K. Raymon, R. S. Chen, L. Corral, M. A. Shirley, R. Krishna Narla, J. Gamez, G. W. Muller, D. I. Stirling, et al. The Synthetic Compound CC-5079 Is a Potent Inhibitor of Tubulin Polymerization and Tumor Necrosis Factor-{alpha} Production with Antitumor Activity Cancer Res., January 15, 2006; 66(2): 951 - 959. [Abstract] [Full Text] [PDF] L. Altucci, A. Rossin, O. Hirsch, A. Nebbioso, D. Vitoux, E. Wilhelm, F. Guidez, M. De Simone, E. M. Schiavone, D. Grimwade, et al. Rexinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase A-Mediated Desubordination of Retinoid X Receptor Cancer Res., October 1, 2005; 65(19): 8754 - 8765. [Abstract] [Full Text] [PDF] A. L. Miller, M. S. Webb, A. J. Copik, Y. Wang, B. H. Johnson, R. Kumar, and E. B. Thompson p38 Mitogen-Activated Protein Kinase (MAPK) Is a Key Mediator in Glucocorticoid-Induced Apoptosis of Lymphoid Cells: Correlation between p38 MAPK Activation and Site-Specific Phosphorylation of the Human Glucocorticoid Receptor at Serine 211 Mol. Endocrinol., June 1, 2005; 19(6): 1569 - 1583. [Abstract] [Full Text] [PDF] S. N. Kip, L. W. Hunter, Q. Ren, P. C. Harris, S. Somlo, V. E. Torres, G. C. Sieck, and Q. Qian [Ca2+]i Reduction Increases Cellular Proliferation and Apoptosis in Vascular Smooth Muscle Cells: Relevance to the ADPKD Phenotype Circ. Res., April 29, 2005; 96(8): 873 - 880. [Abstract] [Full Text] [PDF] P. G. Smith, F. Wang, K. N. Wilkinson, K. J. Savage, U. Klein, D. S. Neuberg, G. Bollag, M. A. Shipp, and R. C. T. Aguiar The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma Blood, January 1, 2005; 105(1): 308 - 316. [Abstract] [Full Text] [PDF] L. Zhang and P. A. Insel The Pro-apoptotic Protein Bim Is a Convergence Point for cAMP/Protein Kinase A- and Glucocorticoid-promoted Apoptosis of Lymphoid Cells J. Biol. Chem., May 14, 2004; 279(20): 20858 - 20865. [Abstract] [Full Text] [PDF] J. Arp, M. G. Kirchhof, M. L. Baroja, S. H. Nazarian, T. A. Chau, C. A. Strathdee, E. H. Ball, and J. Madrenas Regulation of T-Cell Activation by Phosphodiesterase 4B2 Requires Its Dynamic Redistribution during Immunological Synapse Formation Mol. Cell. Biol., November 15, 2003; 23(22): 8042 - 8057. [Abstract] [Full Text] [PDF] E.-Y. Moon and A. Lerner PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A Blood, May 15, 2003; 101(10): 4122 - 4130. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020